Published in Biochim Biophys Acta on October 25, 2008
Clinical translation of stem cells in neurodegenerative disorders. Cell Stem Cell (2012) 1.01
A synopsis on the role of tyrosine hydroxylase in Parkinson's disease. CNS Neurol Disord Drug Targets (2012) 0.93
Motoneuron replacement for reinnervation of skeletal muscle in adult rats. J Neuropathol Exp Neurol (2012) 0.83
Opposite effects of bone marrow-derived cells transplantation in MPTP-rat model of Parkinson's disease: a comparison study of mononuclear and mesenchymal stem cells. Int J Med Sci (2014) 0.77
Characterization of Porcine Ventral Mesencephalic Precursor Cells following Long-Term Propagation in 3D Culture. Stem Cells Int (2012) 0.76
Transplanting intact donor tissue enhances dopamine cell survival and the predictability of motor improvements in a rat model of Parkinson's disease. PLoS One (2012) 0.76
Targeting the vasculature to improve neural progenitor transplant survival. Transl Neurosci (2015) 0.75
Treating non-motor symptoms of Parkinson's disease with transplantation of stem cells. Expert Rev Neurother (2015) 0.75
Basic science in Parkinson's disease: its impact on clinical practice. J Neurol (2011) 0.75
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord (2012) 5.12
Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. Hum Mol Genet (2010) 3.34
The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain (2009) 3.03
The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain (2003) 2.81
L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease. Neuropsychologia (2003) 2.55
Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease. J Neurosci (2005) 2.34
Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry. J Neurosci (2003) 2.22
The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry (2013) 2.20
A novel neuroprotective therapy for Parkinson's disease using a viral noncoding RNA that protects mitochondrial complex I activity. J Exp Med (2011) 2.10
The natural history of treated Parkinson's disease in an incident, community based cohort. J Neurol Neurosurg Psychiatry (2011) 2.08
Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms. Mov Disord (2013) 1.98
Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol (2007) 1.95
Microglial activation in presymptomatic Huntington's disease gene carriers. Brain (2007) 1.93
Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET. Brain (2002) 1.75
L-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson's disease. Neuropsychopharmacology (2006) 1.66
Striatal contributions to working memory: a functional magnetic resonance imaging study in humans. Eur J Neurosci (2004) 1.64
Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol (2011) 1.62
Mutant huntingtin is present in neuronal grafts in Huntington disease patients. Ann Neurol (2014) 1.55
Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. Lancet Neurol (2012) 1.54
Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson's disease. Neuropsychologia (2004) 1.54
Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology (2013) 1.53
Catechol O-methyltransferase Val158Met genotype influences frontoparietal activity during planning in patients with Parkinson's disease. J Neurosci (2007) 1.50
Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. Brain (2013) 1.46
A genome wide linkage disequilibrium screen in Parkinson's disease. J Neurol (2005) 1.41
The emerging technologies of neural xenografting and stem cell transplantation for treating neurodegenerative disorders. Drugs Today (Barc) (2004) 1.40
Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopment. Brain (2010) 1.35
Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study. Hum Brain Mapp (2011) 1.32
Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGF. Proc Natl Acad Sci U S A (2009) 1.32
Patients beware: commercialized stem cell treatments on the web. Cell Stem Cell (2010) 1.32
The spectrum of nonmotor symptoms in early Parkinson disease. Neurology (2013) 1.29
Neural grafting in Parkinson's disease Problems and possibilities. Prog Brain Res (2010) 1.28
Attentional control in Parkinson's disease is dependent on COMT val 158 met genotype. Brain (2008) 1.28
The heterogeneity of idiopathic Parkinson's disease. J Neurol (2002) 1.28
Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease. J Neurol (2009) 1.27
Neurogenesis in the R6/1 transgenic mouse model of Huntington's disease: effects of environmental enrichment. Eur J Neurosci (2006) 1.23
Habitual versus goal-directed action control in Parkinson disease. J Cogn Neurosci (2010) 1.22
Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. Brain (2006) 1.20
Health-related quality of life in Huntington's disease: Which factors matter most? Mov Disord (2009) 1.19
Developmentally coordinated extrinsic signals drive human pluripotent stem cell differentiation toward authentic DARPP-32+ medium-sized spiny neurons. Development (2013) 1.18
Long-term hibernation of human fetal striatal tissue does not adversely affect its differentiation in vitro or graft survival: implications for clinical trials in Huntington's disease. Cell Transplant (2003) 1.17
GABAergic immunoreactivity is predominant in neurons derived from expanded human neural precursor cells in vitro. Exp Neurol (2003) 1.17
A pathophysiological model of freezing of gait in Parkinson's disease. Parkinsonism Relat Disord (2008) 1.17
The current clinical management of Huntington's disease. Mov Disord (2008) 1.16
Hypothalamic involvement in Huntington's disease: an in vivo PET study. Brain (2008) 1.15
Skin and platelet alpha-synuclein as peripheral biomarkers of Parkinson's disease. Neurosci Lett (2005) 1.15
Defective emotion recognition in early HD is neuropsychologically and anatomically generic. Neuropsychologia (2008) 1.15
Whole-brain atrophy as a measure of progression in premanifest and early Huntington's disease. Mov Disord (2009) 1.14
Systematic review and UK-based study of PARK2 (parkin), PINK1, PARK7 (DJ-1) and LRRK2 in early-onset Parkinson's disease. Mov Disord (2012) 1.14
Planning ability in Parkinson's disease is influenced by the COMT val158met polymorphism. Mov Disord (2004) 1.14
Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Brain (2003) 1.13
Huntington's disease patients have selective problems with insight. Mov Disord (2006) 1.12
Imaging microglial activation in Huntington's disease. Brain Res Bull (2006) 1.12
Abnormalities of neurogenesis in the R6/2 mouse model of Huntington's disease are attributable to the in vivo microenvironment. J Neurosci (2005) 1.12
The metabolic profile of early Huntington's disease--a combined human and transgenic mouse study. Exp Neurol (2008) 1.11
Visual hallucinations predict increased benefits from rivastigmine in Parkinson's disease dementia. Nat Clin Pract Neurol (2007) 1.11
Decreased hippocampal cell proliferation in R6/1 Huntington's mice. Neuroreport (2004) 1.10
Task-set switching deficits in early-stage Huntington's disease: implications for basal ganglia function. J Cogn Neurosci (2003) 1.10
The BDNF Val66Met polymorphism has a gender specific influence on planning ability in Parkinson's disease. J Neurol (2005) 1.09
The progression of regional atrophy in premanifest and early Huntington's disease: a longitudinal voxel-based morphometry study. J Neurol Neurosurg Psychiatry (2009) 1.09
Using executive heterogeneity to explore the nature of working memory deficits in Parkinson's disease. Neuropsychologia (2003) 1.06
Neurotrophic factors as a therapeutic target for Parkinson's disease. Expert Opin Ther Targets (2008) 1.05
Health-related quality of life in Huntington's disease: a comparison of two generic instruments, SF-36 and SIP. Mov Disord (2004) 1.05
White matter pathology in Parkinson's disease: the effect of imaging protocol differences and relevance to executive function. Neuroimage (2012) 1.04
Verbal fluency in Huntington's disease: a longitudinal analysis of phonemic and semantic clustering and switching. Neuropsychologia (2002) 1.02
Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options. CNS Drugs (2006) 1.01
The relation between anger and different forms of disgust: implications for emotion recognition impairments in Huntington's disease. Neuropsychologia (2010) 1.01
Clinical translation of stem cells in neurodegenerative disorders. Cell Stem Cell (2012) 1.01
Cognitive impairment in Parkinson's disease: the dual syndrome hypothesis. Neurodegener Dis (2012) 1.00
Two-stage association study and meta-analysis of mitochondrial DNA variants in Parkinson disease. Neurology (2013) 1.00
Neural cells from primary human striatal xenografts migrate extensively in the adult rat CNS. Eur J Neurosci (2002) 0.99
Association of the human leucocyte antigen region with susceptibility to Parkinson's disease. J Neurol Neurosurg Psychiatry (2010) 0.98
Top-down attentional control in Parkinson's disease: salient considerations. J Cogn Neurosci (2010) 0.98
The catechol-O-methyltransferase Val(158)Met polymorphism modulates fronto-cortical dopamine turnover in early Parkinson's disease: a PET study. Brain (2012) 0.97
Olfactory abnormalities in Huntington's disease: decreased plasticity in the primary olfactory cortex of R6/1 transgenic mice and reduced olfactory discrimination in patients. Brain Res (2007) 0.97
Cell therapy in Huntington disease. Neurosurg Focus (2008) 0.97
The spectrum of cognitive impairment in Lewy body diseases. Mov Disord (2014) 0.96
Dopaminergic modulation of neurogenesis in the subventricular zone of the adult brain. Cell Cycle (2009) 0.95
Genetic and pathological links between Parkinson's disease and the lysosomal disorder Sanfilippo syndrome. Mov Disord (2011) 0.95
Huntington's disease: changes in saccades and hand-tapping over 3 years. J Neurol (2010) 0.94
Asymptomatic sleep abnormalities are a common early feature in patients with Huntington's disease. Curr Neurol Neurosci Rep (2011) 0.94
Cell-based therapies for Parkinson's disease. Expert Rev Neurother (2011) 0.92
The importance of A9 dopaminergic neurons in mediating the functional benefits of fetal ventral mesencephalon transplants and levodopa-induced dyskinesias. Neurobiol Dis (2006) 0.92
The Addenbrooke's Cognitive Examination for the differential diagnosis and longitudinal assessment of patients with parkinsonian disorders. J Neurol Neurosurg Psychiatry (2013) 0.92
Exogenous neuropeptide Y promotes in vivo hippocampal neurogenesis. Hippocampus (2011) 0.92
Biomarkers in Huntington's and Parkinson's Disease. Ann N Y Acad Sci (2009) 0.91
Continuing trials of GDNF in Parkinson's disease. Lancet Neurol (2006) 0.90
Automated quantification of caudate atrophy by local registration of serial MRI: evaluation and application in Huntington's disease. Neuroimage (2009) 0.90
The use of the Actiwatch-Neurologica system to objectively assess the involuntary movements and sleep-wake activity in patients with mild-moderate Huntington's disease. J Neurol (2005) 0.90
Relationship between CAG repeat length and brain volume in premanifest and early Huntington's disease. J Neurol (2009) 0.89
The cellular repair of the brain in Parkinson's disease--past, present and future. Transpl Immunol (2004) 0.89
Switching between abstract rules reflects disease severity but not dopaminergic status in Parkinson's disease. Neuropsychologia (2009) 0.89
Saccadic latency in Parkinson's disease correlates with executive function and brain atrophy, but not motor severity. Neurobiol Dis (2011) 0.89
Selective serotonin reuptake inhibition modulates response inhibition in Parkinson's disease. Brain (2014) 0.89
Saccadometry: a new tool for evaluating presymptomatic Huntington patients. Neuroreport (2007) 0.88
The potential for circuit reconstruction by expanded neural precursor cells explored through porcine xenografts in a rat model of Parkinson's disease. Exp Neurol (2002) 0.88
Increased thirst and drinking in Huntington's disease and the R6/2 mouse. Brain Res Bull (2008) 0.88
The Current Status of Neural Grafting in the Treatment of Huntington's Disease. A Review. Front Integr Neurosci (2011) 0.87
Intracellular SERS nanoprobes for distinction of different neuronal cell types. Nano Lett (2013) 0.87
Time course of dopamine neuron loss and glial response in the 6-OHDA striatal mouse model of Parkinson's disease. Eur J Neurosci (2013) 0.87
The future of cell-based transplantation therapies for neurodegenerative disorders. J Hematother Stem Cell Res (2003) 0.87